DynoChem Extends Software Agreement with Bristol-Myers Squibb
News Jul 11, 2007
The agreement will allow Bristol-Myers Squibb to expand deployment of DynoChem process modeling software throughout its Research and Development group and for scale-up into manufacturing.
Bristol-Myers Squibb noted that in meeting the challenges inherent in the scale-up of synthetic pharmaceutical processes, operation modeling allows the company to make use of knowledge and resources to answer critical questions.
In addition, the incorporation of modeling technologies such as DynoChem across Bristol-Myers Squibb’s process development enterprise helps achieve the company’s development goals.
PFD Managing Director Dr. Joe Hannon said, “We are pleased to have the opportunity to expand our relationship with BMS and continue our commitment to their pharmaceutical product development effort. We believe this agreement further validates DynoChem’s success in achieving our customers’ goals of accelerating process development and lowering drug development costs.”
University of Wisconsin–Madison Professor of Chemistry Shannon Stahl has received the Steenbock Professorship in Chemical Sciences. In addition to advancing the fundamental science in this area, Stahl has been involved in numerous industrial collaborations that have led to practical applications, including target applications relevant to pharmaceutical synthesis.READ MORE